2022 World Conference on Lung Cancer (ePosters)-EP08.02-153. The Efficacy and Safety of EGFR-TKIs plus Anlotinib in Maintenance Therapy for Oligoprogressive Advanced or Metastatic EGFR Mutant NSCLC

EP08.02-153. The Efficacy and Safety of EGFR-TKIs plus Anlotinib in Maintenance Therapy for Oligoprogressive Advanced or Metastatic EGFR Mutant NSCLC

Back to course

Pdf Summary

This study evaluates the efficacy and safety of combining anlotinib, an antiangiogenic agent, with EGFR-TKIs as maintenance therapy for EGFR mutant NSCLC. EGFR-TKIs are commonly used as the first-line treatment for this type of lung cancer. However, resistance to EGFR-TKIs eventually develops, and there are limited options available for further targeted therapy. Previous studies have shown that continuing EGFR-TKIs maintenance therapy after oligoprogressive disease can extend progression-free survival (PFS) by 3.1 months.<br /><br />Anlotinib is an oral small molecule antiangiogenic agent that has shown effectiveness in NSCLC. This study is designed as a prospective, single-arm clinical trial and aims to evaluate the efficacy and safety of combining anlotinib with EGFR-TKIs in patients with oligoprogressive advanced or metastatic EGFR mutant NSCLC. The primary endpoint is PFS, while secondary endpoints include overall survival (OS) and safety. The study also aims to identify potential molecular markers.<br /><br />So far, seven patients have been enrolled in the trial, and no significant adverse events have been observed. The most common adverse reactions reported were skin rash and peeling, which resolved spontaneously or with reduced dosage after two treatment cycles. The trial is ongoing, and patient enrollment and follow-up are still in progress.<br /><br />In summary, this study aims to determine the efficacy and safety of combining anlotinib with EGFR-TKIs as maintenance therapy for EGFR mutant NSCLC after EGFR-TKIs therapy. So far, the treatment has been well-tolerated by the enrolled patients, indicating its potential safety. Further evaluation is needed as the trial continues.

Asset Subtitle

Zhaoxia Wang

Meta Tag

Speaker Zhaoxia Wang

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

anlotinib

EGFR-TKIs

maintenance therapy

EGFR mutant NSCLC

lung cancer

oligoprogressive disease

progression-free survival

NSCLC

clinical trial

molecular markers